A polymorphism in the promoter is associated with EZH2 expression but not with outcome in advanced pancreatic cancer patients

Pharmacogenomics

Volumn 15, Issue 5, 2014, Pages 609-618

  Maftouh, Mina ^a   Avan, Amir ^a   Funel, Niccola ^b   Paolicchi, Elisa ^b   Vasile, Enrico ^b   Pacetti, Paola ^c   Vaccaro, Vanja ^d   Faviana, Pinuccia ^b   Campani, Daniela ^b   Caponi, Sara ^b   Mambrini, Andrea ^c   Boggi, Ugo ^b   Cantore, Maurizio ^c   Milella, Michele ^d   Peters, Godefridus J ^a   Reni, Michele ^e   Giovannetti, Elisa ^a,b  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF PISA   (Italy)

^c Piazza Sacco e Vanzetti   (Italy)

^d REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^e SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

EZH2; gemcitabine based chemotherapy; locally advanced metastatic; outcome; pancreatic ductal adenocarcinoma; SNP

Indexed keywords

CAPECITABINE; CISPLATIN; DOCETAXEL; EPIRUBICIN; GEMCITABINE; MICRORNA 101; TRANSCRIPTION FACTOR EZH2; ANTINEOPLASTIC ANTIMETABOLITE; DEOXYCYTIDINE; DNA; EZH2 PROTEIN, HUMAN; MICRORNA; MIRN101 MICRORNA, HUMAN; POLYCOMB REPRESSIVE COMPLEX 2;

ADVANCED CANCER; AGED; ARTICLE; BLOOD SAMPLING; CANCER LOCALIZATION; CANCER PROGNOSIS; CANCER SURVIVAL; COHORT ANALYSIS; CONTROLLED STUDY; EZH2 GENE; FEMALE; GENE CONTROL; GENE EXPRESSION; GENETIC ASSOCIATION; GENETIC CORRELATION; HUMAN; LASER MICRODISSECTION; MAJOR CLINICAL STUDY; MALE; METASTASIS; MONOTHERAPY; OUTCOME ASSESSMENT; PANCREAS ADENOCARCINOMA; POLYPHARMACY; PREDICTION; PROMOTER REGION; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SINGLE NUCLEOTIDE POLYMORPHISM; ANALOGS AND DERIVATIVES; BIOSYNTHESIS; DISEASE COURSE; GENETIC POLYMORPHISM; GENETICS; MIDDLE AGED; PANCREATIC NEOPLASMS; PATHOLOGY; SURVIVAL; TREATMENT OUTCOME;

AGED; ANTIMETABOLITES, ANTINEOPLASTIC; COHORT STUDIES; DEOXYCYTIDINE; DISEASE PROGRESSION; DNA; FEMALE; HUMANS; MALE; MICRORNAS; MIDDLE AGED; PANCREATIC NEOPLASMS; POLYCOMB REPRESSIVE COMPLEX 2; POLYMORPHISM, GENETIC; PROMOTER REGIONS, GENETIC; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84899803770     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.13.225     Document Type: Article

References (27)

1. Vincent A, Herman J, Schulick R, Hruban RH, Goggins M. Pancreatic cancer. Lancet 378(9791), 607-620 (2011).
2. Makohon-Moore A, Brosnan JA, Iacobuzio-Donahue CA. Pancreatic cancer genomics: Insights and opportunities for clinical translation. Genome Med. 5(33), 26 (2013).
3. Toll AD, Dasgupta A, Potoczek M. et al. Implications of enhancer of zeste homologue 2 expression in pancreatic ductal adenocarcinoma. Hum. Pathol. 41(9), 1205-1209 (2010).
4. Viré E, Brenner C, Deplus R. et al. The Polycomb group protein EZH2 directly controls DNA methylation. Nature 16(7078), 871-874 (2006).
5. Qi W, Chan H, Teng L. et al. Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation. Proc. Natl Acad. Sci. USA 109(52), 21360-21365 (2012).
6. Chang CJ, Yang JY, Xia W. et al. EZH2 promotes expansion of breast tumor initiating cells through activation of RAF1-b-catenin signaling. Cancer Cell 19(1), 86-100 (2011).
7. Avan A, Crea F, Paolicchi E. et al. Molecular mechanisms involved in the synergistic interaction of the EZH2 inhibitor 3-deazaneplanocin A with gemcitabine in pancreatic cancer cells. Mol. Cancer Ther. 11(8), 1735-1746 (2012).
8. Ougolkov AV, Bilim VN, Billadeau DD. Regulation of pancreatic tumor cell proliferation and chemoresistance by the histone methyltransferase EZH2. Clin. Cancer Res. 14(21), 6790-6796 (2008).
9. Yoon KA, Gil HJ, Han J, Park J, Lee JS. Genetic polymorphisms in the polycomb group gene EZH2 and the risk of lung cancer. J. Thorac. Oncol. 5(1), 10-16 (2010).
10. Crea F, Fornaro L, Paolicchi E. et al. An EZH2 polymorphism is associated with clinical outcome in metastatic colorectal cancer patients. Ann. Oncol. 23(5), 1207-1213 (2012).
11. Fornaro L, Crea F, Masi G. et al. EZH2 polymorphism and benefit from bevacizumab in colorectal cancer: Another piece to the puzzle. Ann. Oncol. 23(5), 1370-1371 (2012).
12. Cardoso C, Mignon C, Hetet G. et al. The human EZH2 gene: Genomic organisation and revised mapping in 7q35 within the critical region for malignant myeloid disorders. Eur. J. Hum. Genet. 8(3), 174-180 (2000).
13. Yang CH, Cheng YH, Chuang LY, Chang HW. Drug-SNPing: An integrated drug-based, protein interaction-based tagSNP-based pharmacogenomics platform for SNP genotyping. Bioinformatics 29(6), 758-764 (2013).
14. Yu YL, Su KJ, Hsieh YH. et al. Effects of EZH2 polymorphisms on susceptibility to and pathological development of hepatocellular carcinoma. PLoS ONE 8(9), e74870 (2013).
15. Giovannetti E, Del Tacca M, Mey V. et al. Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine. Cancer Res. 66(7), 3928-3935 (2006).
16. Giovannetti E, Funel N, Peters GJ. et al. MicroRNA-21 in pancreatic cancer: Correlation with clinical outcome and pharmacologic aspects underlying its role in the modulation of gemcitabine activity. Cancer Res. 70(11), 4528-4538 (2010).
17. Avan A, Pacetti P, Reni M. et al. Prognostic factors in gemcitabine-cisplatin polychemotherapy regimens in pancreatic cancer: XPD-Lys751Gln polymorphism strikes back. Int. J. Cancer 133(4), 1016-1022 (2013).
18. Giovannetti E, Pacetti P, Reni M. et al. Association between DNA-repair polymorphisms and survival in pancreatic cancer patients treated with combination chemotherapy. Pharmacogenomics 12(12), 1641-1652 (2011).
19. Qazi AM, Gruzdyn O, Semaan A. et al. Restoration of E-cadherin expression in pancreatic ductal adenocarcinoma treated with microRNA-101. Surgery 152(4), 704-711 (2012).
20. Caponi S, Funel N, Frampton AE. et al. The good, the bad and the ugly: A tale of miR-101, miR-21 and miR-155 in pancreatic intraductal papillary mucinous neoplasms. Ann. Oncol. 24(3), 734-741 (2013).
21. Smits M, Nilsson J, Mir SE. et al. miR-101 is down-regulated in glioblastoma resulting in EZH2-induced proliferation, migration, and angiogenesis. Oncotarget 1(8), 710-720 (2010).
22. Chase A, Cross NC. Aberrations of EZH2 in cancer. Clin. Cancer Res. 17(9), 2613-2618 (2011).
23. Oncomine. www.oncomine.org/resource/login.html
24. Gao L, Antic T, Hyjek E. et al. Immunohistochemical analysis of E-cadherin and zeste homolog 2 expression in endoscopic ultrasound-guided fine-needle aspiration of pancreatic adenocarcinoma. Cancer Cytopathol. doi:10.1002/cncy.21310 (2013) (Epub ahead of print).
25. RNAfold web server. http://rna.tbi.univie.ac.at/cgi-bin/RNAfold. cgi
26. Li CH, To KF, Tong JH. et al. Enhancer of zeste homolog 2 silences microRNA-218 in human pancreatic ductal adenocarcinoma cells by inducing formation of heterochromatin. Gastroenterology 144(5), 1086-1097 (2013).
27. Giovannetti E, Erozenci A, Smit J, Danesi R, Peters GJ. Molecular mechanisms underlying the role of microRNAs (miRNAs) in anticancer drug resistance and implications for clinical practice. Crit. Rev. Oncol. Hematol. 81(2), 103-122 (2012).